STGen Bio Signs 4.6 Billion KRW Biopharmaceutical Manufacturing Contract with Global Pharmaceutical Company

STGen Bio announced on July 2 through a public disclosure that it has signed a contract for contract manufacturing of biopharmaceuticals with a global pharmaceutical company. The total contract amount is 4.6 billion KRW, which is approximately 7.8% of the company's recent sales of 58.8 billion KRW.

Exterior view of the STGen Bio factory. Photo by STGen Bio

The contract period runs from June of this year to November 2026, with an advance payment of approximately 900 million KRW. The client and product names are not disclosed due to confidentiality agreements. This order announcement follows a previous disclosure on June 13 regarding a 9.9 billion KRW contract for contract manufacturing of pharmaceuticals, bringing the total value of recently secured orders to over 14 billion KRW.

Specializing in the biopharmaceutical CMO (contract manufacturing organization) business, STGen Bio demonstrated its global-level quality competitiveness last year by passing inspections by both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

Among domestic CMO companies, STGen Bio is the only one to operate a single-site cGMP-certified manufacturing facility with a one-stop production system that covers everything from drug substance (DS) to finished drug product (DP) in pre-filled syringe (PFS) form. Recently, the company has been actively seeking opportunities to expand into the global market and to broaden collaborations with various partners.

A representative of STGen Bio stated, "STGen Bio provides end-to-end manufacturing services, from DS to DP, and from clinical samples to commercial products, all with the highest quality standards," and emphasized, "We will continue to enhance our service platform across all areas of CMO business to ensure the satisfaction of every client."

This content was produced with the assistance of AI translation services.